Iambic Therapeutics

Iambic Therapeutics runs a molecular superintelligence platform that combines its Enchant and NeuralPLexer AI models with automated, high-throughput chemistry and biology experimentation. The company says the platform produces hundreds of novel compounds per week and tests them across physicochemical, biological and metabolic assays.

Iambic's own pipeline includes IAM1363 for HER2 (Phase 1/1b), IAM217 for KIF18A (IND submitted) and IAM-C1 for CDK2/4 (IND-enabling), all targeting solid tumor cancers. The website also lists drug discovery collaborations among its business activities; revenue terms are not described.

The company was co-founded in October 2019 by Tom Miller (CEO) and Fred Manby (CTO) and is headquartered in San Diego, with a Boston office. Its open roles span San Diego, Boston, a UK office and remote US positions, across medicinal chemistry, machine learning, clinical development, regulatory and finance. The website reports an initial public offering pricing announcement dated October 14, 2026.

Product: Molecular superintelligence drug discovery platform (Enchant, NeuralPLexer) and an in-house pipeline of small-molecule oncology candidates.